Keep up-to-date with BMS Canada
HEPATITIS C CURE RATE OF 97 PER CENT ANNOUNCED IN STUDY OF PATIENTS CO-INFECTED WITH HIV GIVEN 12-WEEK COMBINATION TREATMENT OF DACLATASVIR AND SOFOSBUVIR IN ALLY-2 TRIALPatient population with both infections historically challenging to treat due to drug-drug interactions.
Categories: Hepatitis C
Kirkland, QC – November 26, 2014
MONTREAL, QUEBEC, November 19, 2014
NEW PD-1 IMMUNE CHECKPOINT INHIBITOR OPDIVO (NIVOLUMAB) FIRST TO DEMONSTRATE SURVIVAL BENEFIT IN PHASE 3 TRIAL IN TREATMENT NAÏVE ADVANCED MELANOMAResults of study conducted in Canada, Australia and Europe presented at Society for Melanoma Research and published in The New England Journal of Medicine show one-year survival rate of 73% in patients on Opdivo, versus 42% on dacarbazine and a 58% decrease in the risk of death (Hazard Ratio [HR] = 0.42, p<0.0001).
Categories: Public Communication
Expanded Access Programs
Expanded Access, Named Patient and Emergency Use Programs for Bristol-Myers Squibb Medicines. Find out more.
Events & Programs
BMS Canada is committed to community involvement. Find out more.
Looking for a Great Career?
Bristol-Myers Squibb Canada can offer you the challenge and support you are looking for in a friendly, motivating and exciting atmosphere. Find out more.